Use of the IL‐6R antagonist tocilizumab in hospitalized COVID‐19 patients
Open Access
- 3 August 2020
- journal article
- letter
- Published by Wiley in Journal of Internal Medicine
- Vol. 289 (3), 430-433
- https://doi.org/10.1111/joim.13163
Abstract
Severely ill COVID‐19 patients have a high risk of admission to the intensive‐care unit (ICU) and requirement for mechanical ventilation (MV), with in‐hospital mortality reported as 18‐79% globally.1‐4. Among ICU patients in the United States (US), centers have reported 50% mortality.5,6 Tocilizumab, an IL‐6 receptor (IL‐6R) antagonist, is FDA approved for the management of CAR T‐cell related Cytokine Release Syndrome (CRS) and may have utility in treatment of some COVID‐19 patients. We describe the clinical characteristics and initial outcomes of a cohort of patients treated with tocilizumab at the Swedish Medical Center in Seattle, Washington.Keywords
This publication has 7 references indexed in Scilit:
- Covid-19 in Critically Ill Patients in the Seattle Region — Case SeriesThe New England Journal of Medicine, 2020
- Clinical Characteristics of Coronavirus Disease 2019 in ChinaThe New England Journal of Medicine, 2020
- Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington StateJAMA, 2020
- Critical Care Utilization for the COVID-19 Outbreak in Lombardy, ItalyJAMA, 2020
- Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in ChinaJAMA, 2020
- Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, ChinaJAMA, 2020
- Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort studyThe Lancet, 2020